The manufacturer of OxyContin (oxycodone) - along with members of the Sackler family that have a controlling stake in the firm - proffered the deal at a meeting with state attorneys general last week, according to the broadcaster, which cites two people close to the matter.
Attorneys general representing several states also confirmed the accelerated negotiations.
Youngstown City Law Director Jeff Limbian said combining the cases into one could be beneficial.
The consolidated Cleveland case is In Re National Prescription Opioid Litigation, 17-md-2804, U.S. District Court, Northern District of Ohio (Cleveland).
According to the Centers for Disease Control and Prevention (CDC), 400,000 people in the U.S.
NBC reported that Purdue presented a plan for it to declare Chapter 11 bankruptcy and then restructure into a for-profit "public benefit trust".
The Wall Street Journal said the arrangement would stay in place for seven to 10 years and would be overseen by trustees named by the bankruptcy court. "It is going to those types of programs so we can get people off the drugs and get young people not even started", O'Brien said.Читайте также: These Android apps were clicking on ads behind your back
Representatives for the Sackler family declined to comment and a representative for the state attorneys general did not immediately respond to a request for comment. Purdue is looking for what is called a global settlement, which is an agreement that would end all lawsuits at once. That could grow by $1.5 billion if the family sells Mundipharma, an worldwide drug company that it also owns.
Purdue, which made more than $35 billion from OxyContin sales, would potentially contribute $7 billion to $8 billion.
But Purdue and the Sackler family have consistently denied those accusations, and they framed the proposed settlement as simply a quicker way to help those impacted by the opioid crisis. It's unclear how much Purdue's owners, the Sackler family, would have to pay. Most claim that Purdue and the Sacklers used deceptive marketing practices to downplay the potential harms from opioid painkillers such as OxyContin, a Purdue product.
In a statement, the Stamford, Connecticut-based company said it's prepared to defend itself but sees little good in years of "wasteful litigation and appeals".
On Monday, an Oklahoma judge ordered Johnson & Johnson to pay $572.1 million to the state for deceptively marketing addictive painkillers following the first trial related to the addiction crisis.
Purdue said it was actively working with state attorneys general and other plaintiffs to reach a resolution, without specifying a settlement amount. The sum includes $3 billion from the Sackler family fortune.
In recent months, a number of cultural institutions, including New York's Guggenheim Museum and the Metropolitan Museum of Art, have said they would stop accepting donations from the Sackler family.При любом использовании материалов сайта и дочерних проектов, гиперссылка на обязательна.
«» 2007 - 2019 Copyright.
Автоматизированное извлечение информации сайта запрещено.
Код для вставки в блог